Coagulopathic patients with traumatic intracranial bleeding: Defining the role of recombinant factor VIIa

Journal of Trauma - Injury, Infection and Critical Care

Volumn 63, Issue 4, 2007, Pages 725-732

  Bartal, Carmi ^a   Freedman, John ^b   Bowman, Kim ^b   Cusimano, Michael ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Coagulopathy; Factor VIIa; Intracranial bleeding; Neurosurgery; Subdural hematoma

Indexed keywords

ANTICOAGULANT AGENT; FRESH FROZEN PLASMA; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HEAD INJURY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SUBDURAL HEMATOMA; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTRACRANIAL HEMORRHAGE, TRAUMATIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 37349031078     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e318031ccca     Document Type: Article

References (50)

1. Blajchman MA. Substitutes and alternatives to platelets transfusion in thrombocytopenic patients [review article]. J Thromb Haemost. 2003;1:1637-1641.
2. Von Depka M. Novoseven: mode of action and use in acquired haemophilia. Intensive Care Med. 2002;28:s222-s227.
3. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, Pongtanakul B, Worapongpaiboon S. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thromboasthenia. Blood Coagul Fibrinolysis. 2003;14:187-190.
4. Martinowitch U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII in the control of hemorrhage associated with massive trauma. Can J Anaesth. 2002;49:s15-s20.
5. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma. 2002;52:400-405.
6. Midathda MV, Metha P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol. 2004;121:124-137.
7. Anantharaju A, Metha K, Mindikoglu AL, Van Thiel D. Use of activated recombinant human factor VII for colonic polypectomies in patients with cirrhosis and coagulopathy. Dig Dis Sci. 2003;48:1414-1424.
8. Veldman A, Fischer D, Voight B, Schlosser R, Allendorf A, Kreuz W. Life threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28:1635-1637.
9. Veldman A, Fischer D, Voight B, Schlosser R, Allendorf A, Kreuz W. Life threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002;28:1635-1637.
10. Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Trans Med Rev. 1993;7:78-83.
11. Arkin S, Cooper HA, Miller S, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the NovoSeven emergency-use program. Haemostasis. 1998;28:93-98.
12. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin related coagulopathy in patients with subdural hematoma. Med Sci Monit. 2002;8:98-100.
13. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98:737-740.
14. Huang WY, Kruskall MS, Bauer KA, Shaz BH. The use of recombinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion. 2004;44:1544-1546.
15. Kessler C. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant factor VII? Intensive Care Med. 2002;28:s228-s234.
16. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa for rapid preoperative correction of warfarin related coagulopathy in patients with acute subdural hematoma. Med Sci Monit. 2002;8:98-100.
17. Mayer SA, Burn NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke. 2005;36:74-79.
18. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke. 2003;34:224-229.
19. Yasuda CL, Morita ME, Nishimori FY, Yasuda AM, Alves HL. Chronic subdural hematoma: study of 161 patients and the relationship with coagulation abnormalities. Arq Qneurosiquitar. 2003;61:1011-1014.
20. Matheisen T, Benedikrsdonir K, Linquist M, Von Holst H. Intracranial traumatic and non-traumatic hemorrhagic complications of warfarin treatment. Acta Neurol Scand. 1995;91:208-214.
21. Boulis N, Bobek M, Schmaier A, Hoff J. Use of factor IX complex in warfarin related intracranial hemorrhage. Neurosurgery. 1999;45:1113-1119.
22. Kawamata T, Takeshita M, Kubo O, et al. Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol. 1999;44:438-444.
23. Boulis NM, Bobek MP, Schmaier A, et al. Use of factor IX complex in warfarin related intracranial hemorrhage. Neurosurgery. 1999;45:1113-1119.
24. Fredriksson K, Norrving B, Stombland L-G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;23:972-977.
25. Kohler M, Hellstern P, Lechler E, et al. Thromboembolic complications associated with the use of prothrombin complex and factor IX. Thromb Haemost. 1998;80:399-402.
26. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thrombophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469-477.
27. Berntrop E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia. 2003;9:353-359.
28. Roberts HR, Monroe DM III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol. 2004;41(Suppl 1):101-108.
29. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547.
30. Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis. 1996;26(Suppl 1):102-108.
31. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis. 1998;9:741-748.
32. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55:638-648.
33. Siegel LJ, Gerigk L, Tuettenberg J, Dempfle CE, Scharf J, Fiedler F. Cerebral sinus thrombosis in a trauma patient after recombinant activated factor VII infusion. Anesthesiology. 2004;100:2.
34. Roberts HR. Recombinant factor VIIa (NovoSeven) and the safety of the treatment. Semin Hematol. 2001;38:48-50.
35. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. New Engl J Med. 2005;352:777-785.
36. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost. 1999;82:1775-1776.
37. Clark AD, Gordon WC, Walker ID, Tait RC. "Last-ditch" use of recombinant factor VIIa in patients with massive hemorrhage is ineffective. Vox Sang. 2004;86:120-124.
38. Fewel ME, Park P. The emerging role of recombinantactivated factor VII in neurocritical care. Neurocrit Care. 2004;1:19-30.
39. Goodnough LT. Treatment of critical bleeding in the future intensive care unit. Intensive Care Med. 2002;28:s221.
40. Wilberger JE, Harris M, Diamond DL. Acute subdural hematoma: mortality, morbidity and operative timing. J Neurosurg. 1991;74:212-218.
41. Howard MA III, Gross AS, Dacey RG Jr, et al. Acute subduralhematomas: an age-dependent clinical entity. J Neurosurg. 1989;71:858-863.
42. Berntrop E, Recombinant factor VIIa in the treatment of warfarin bleeding. Semin Thromb Hemost. 2000;26:433-435.
43. Gautille T, Klauber MR, et al. The outcome of severe closed head injury. J Neurosurg. 1991;75(Suppl):S28-S36.
44. Lin J, Hanigan CW, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98:737-740.
45. Kessler C. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant factor VII? Intensive Care Med. 2002;28:s228-s234.
46. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-890.
47. Broderick JP, Adams HP Jr, Barsan W, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30:905-915.
48. Macik BG, Lindley CM, Lusher J, et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagul Fibrinolysis. 1993;4:521-527.
49. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery. 2003;53:34-39.
50. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27:1783-1787.